Share ownership Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 20:00:55 13/03/2026 GMT			5-day change	1st Jan Change
115.61 ^USD	-0.26%		-0.16%	+9.83%

03-12	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03-10	Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says	MT

Share class: Merck & Co., Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,577,103,522	2,528,032,964 ( 70.67 %)	1,045,073,377 ( 29.22 %)	70.67 %

Major shareholders: Merck & Co., Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.29 %	254,322,763	10.29 %	31 490 M $
BlackRock Advisors LLC 6.509 %	160,933,559	6.509 %	19 927 M $
STATE STREET CORPORATION 4.855 %	120,040,168	4.855 %	14 863 M $
Wellington Trust Co., NA 3.496 %	86,435,458	3.496 %	10 702 M $
Geode Capital Management LLC 2.429 %	60,047,984	2.429 %	7 435 M $
BlackRock Life Ltd. 2.08 %	51,436,428	2.08 %	6 369 M $
Charles Schwab Investment Management, Inc. 1.964 %	48,563,804	1.964 %	6 013 M $
Eaton Vance Management 1.818 %	44,946,021	1.818 %	5 565 M $
Fidelity Management & Research Co. LLC 1.649 %	40,767,953	1.649 %	5 048 M $
Norges Bank (13F) 1.536 %	37,981,502	1.536 %	4 703 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.00109 %	215,530	0.00109 %	3 M $
Safra Asset CTVM SA (Investment Management) 0.000294 %	58,100	0.000294 %	883 903 $
XP Allocation Asset Management Ltda. 0.000027 %	5,293	0.000027 %	80 525 $
E2M Investimentos Ltda. 0.000004 %	700	0.000004 %	10 649 $

Breakdown by shareholder type

Institutional	64.07%
Other	8.52%
State Street Corp.	4.86%
Swedbank AB	0.31%
Sumitomo Mitsui Trust Group, Inc.	0.28%
Schweizerische Nationalbank	0.28%
Governments	0.15%
SEI Investments Co.	0.11%
The Bank of Nova Scotia	0.08%
Danske Bank A/S	0.08%
Manulife Financial Corp.	0.07%
Skandinaviska Enskilda Banken AB	0.07%
Regions Financial Corp.	0.05%
Individuals	0.05%
Münchener Rückversicherungs-Gesellschaft AG	0.04%
ING Groep NV	0.03%
First Financial Bankshares, Inc.	0.03%
Old Republic International Corp.	0.03%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Zurich Insurance Group AG	0.02%
Fifth Third Bancorp	0.02%
Peapack-Gladstone Financial Corp.	0.02%
ABN AMRO Bank NV	0.01%
Ally Financial, Inc.	0.01%
The Allstate Corp.	0.01%
Fairfax Financial Holdings Ltd.	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Rathbones Group Plc	0.01%
Hancock Whitney Corp.	0.01%
Commerzbank AG	0.01%
Unknown	20.72%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	59.58%
United Kingdom	7.86%
Canada	2.41%
Norway	1.73%
Sweden	1.04%
France	0.96%
Australia	0.79%
Japan	0.79%
Switzerland	0.75%
Denmark	0.66%
Germany	0.48%
Netherlands	0.34%
Hong Kong	0.33%
South Korea	0.32%
Ireland	0.19%
Italy	0.18%
Luxembourg	0.16%
Malaysia	0.1%
Belgium	0.1%
Spain	0.09%
Finland	0.09%
New Zealand	0.07%
Singapore	0.06%
Individuals	0.05%
Austria	0.05%
Czech Republic	0.03%
Liechtenstein	0.02%
Saudi Arabia	0.01%
Brazil	0.01%
Puerto Rico	0.01%
South Africa	0.01%
Slovenia	0.01%
China	0.01%

Based on 1000 largest holdings

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

04:00am - Ex-dividend date - 0.85 USD

More about the company